𝔖 Bobbio Scriptorium
✦   LIBER   ✦

TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial

✍ Scribed by C Warren Olanow; Anthony HV Schapira; Peter A LeWitt; Karl Kieburtz; Dirk Sauer; Gianfranco Olivieri; Harald Pohlmann; Jean Hubble

Book ID
114408471
Publisher
The Lancet
Year
2006
Tongue
English
Weight
145 KB
Volume
5
Category
Article
ISSN
1474-4465

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Sarizotan as a treatment for dyskinesias
Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial
✍ Christopher G. Goetz; Philippe Damier; Christine Hicking; Eugene Laska; Thomas M πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 117 KB πŸ‘ 1 views

## Abstract The objective of this study is to conduct a dose‐finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. Sarizotan is a novel compound with full 5‐HT~1A~ agonist properties and additio